aTyr Pharma, Inc.

aTyr Pharma, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. aTyr Pharma, Inc. is not very popular among insiders. aTyr Pharma, Inc. is a mediocre stock to choose.

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build...

News

aTyr Pharma announces Nasdaq stock ticker symbol change

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

aTyr Pharma announces Nasdaq ticker symbol change to “ATYR”

Seeking Alpha - Healthcare aTyr Pharma announces Nasdaq ticker symbol change to “ATYR”...\n more…

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR

Globe Newswire Ticker symbol change to take effect on Wednesday, June 5, 2024SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) ( aTyr or the Company ), a clinical stage biotechnology...\n more…

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) ( aTyr or the Company ), a clinical stage biotechnology company engaged in the discovery and development of...\n more…

aTyr Pharma to present poster of efzofitimod's mechanism of action

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

Globe Newswire Findings further demonstrate that NRP2 is an important new immune target in ILD and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefitSAN DIEGO, May 15, 2024 (GLOBE...\n more…